Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
Published on 08/21/2026 at 07:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) stock is trading close to its recent high as of August 20, 2026, with investors weighing double-digit second quarter 2026 revenue growth and a steady dividend ahead of the August 21, 2026 ex-dividend date.
Q2 2026 results show double-digit growth
In an August 4, 2026 financial release, Amgen reported that total revenues for the second quarter of 2026 rose 10% to $10.1 billion compared with the second quarter of 2025. This Q2 2026 update confirms that the company is expanding its top line at a solid pace, with growth well into the double digits versus the prior-year period.
The same second quarter 2026 release highlights that this revenue performance builds on the company’s broader 2026 trajectory, signaling that the most recent quarter represents a continuation rather than a one-off spike. Investors tracking fundamentals can therefore treat the $10.1 billion Q2 2026 revenue base as a current metric within the standard freshness window.
Dividend ex-date on August 21, 2026
Alongside the earnings momentum, Amgen is offering shareholders a quarterly cash dividend that goes ex-dividend on August 21, 2026. A market-news summary notes that shareholders of record on August 21, 2026 will receive a dividend of $2.52 per share, scheduled for payment on September 11, 2026. This dividend overview underscores that the board is maintaining a meaningful cash return.
Separate trading commentary indicates that this quarterly dividend of $2.52 per share translates into an annualized dividend of $10.08 per share and an indicated yield of 2.3% at recent share prices. This same report also reiterates that the ex-dividend date is August 21, 2026, making the timing directly relevant for income-focused investors and options traders positioning around the payout.
Shares trade close to recent highs
Recent market data compiled on August 20, 2026 show Amgen stock trading on the Nasdaq at $440.88 per share, with an intraday range from $427.99 to $443.19 on that date. This trading overview places the shares only slightly below their latest peak, reinforcing that the stock is still near record territory after a strong move higher.
The same trading snapshot lists Amgen’s market capitalization at $239.17 billion as of August 20, 2026, highlighting the company’s position among the largest global biopharmaceutical firms. With a price near $440 and an indicated dividend yield of 2.3%, investors are effectively paying a large-cap valuation for exposure to double-digit current revenue growth and a consistent cash return profile.
Options-trading commentary dated August 20, 2026 notes that shares traded at $433.73 during mid-day trading on that session, which is modestly below the $440.88 level cited in the later overview. This mid-day quote suggests that Amgen’s share price fluctuated within a relatively tight range over the course of the day but remained in the low-to-mid $430s and $440s, near its 52-week high zone.
Analyst and valuation context
Consensus data summarized in recent coverage show that analysts currently rate Amgen on average as a Hold, with a consensus price target of $379.36 in one snapshot and $380.43 in another, both as of August 20, 2026. This analyst consensus summary indicates that the stock is trading well above the prevailing average target, given the recent price near $442.36 referenced in the same report.
The same analyst overview mentions that Amgen shares recently traded near $442, close to their 52-week high, while the average price target stayed below $400. This comparison means that Amgen stock is currently trading more than $60 above the consensus target range, a gap that highlights how market pricing is factoring in stronger growth and dividend visibility than analysts’ models have embedded so far.
Additional commentary points out that Amgen recently increased its dividend and that the quarterly payment of $2.52 per share aligns with a yield of 2.3% at the current price region. When combined with the 10% year-over-year revenue increase in Q2 2026, this payout supports an investment case centered on both income and growth, even though the valuation multiple implied by a price above $440 may be higher than in prior years.
Product and pipeline backdrop
While the day’s main drivers are earnings and the dividend, Amgen’s long-term equity story continues to rest on its portfolio of biologic therapies and pipeline assets across oncology, cardiovascular disease, and autoimmune conditions. Recent communications emphasize the role of its established biologics alongside newer therapies and biosimilars in driving the $10.1 billion revenue figure for the second quarter of 2026, although the exact product-by-product breakdown sits within the detailed tables of the earnings release.
For retail investors, one illustrative angle is Amgen’s focus on chronic disease treatments that generate recurring revenue streams. This positioning can help smooth out quarterly volatility and provide a foundation for sustaining dividends such as the current $2.52 per-share payment, even as the company invests in late-stage clinical programs and potential future launches.
Amgen therapies as a representative product cluster
In the broader biopharmaceutical landscape, Amgen’s marketed therapies form a representative cluster of products that underpin its current financials. The second quarter 2026 revenue base of $10.1 billion reflects contributions from a mix of oncology, hematology, inflammatory, and cardiovascular medicines, alongside biosimilars that increase access to biologic treatments.
Investors frequently monitor how these product lines perform in the latest quarter, since sustained volume growth and stable pricing dynamics across key therapies can support both the dividend stream and further share-price appreciation from levels close to $440. As the company continues to develop and commercialize additional pipeline assets, this multi-therapy platform remains central to the long-term case for Amgen shares.
Nasdaq listing and recent price level
Amgen stock is listed on the Nasdaq in the United States, and market data as of August 20, 2026 show the shares at $440.88 in regular trading hours. This quote overview aligns with the trading range and price levels reported in more detailed market snapshots, placing the company’s equity valuation at $239.17 billion at that date.
With the ex-dividend date on August 21, 2026 for the $2.52 per-share cash payout, investors who hold Amgen stock through the record date will secure an annualized dividend of $10.08 per share. At the latest verified price of $440.88 as of August 20, 2026, that payment corresponds to a yield of 2.3%, reinforcing the stock’s income component at a time when revenue growth is running at 10% year over year in the second quarter of 2026.
Read more
More on Amgen stock
Representative product focus
Amgen’s treatment portfolio, spanning biologic medicines and biosimilars, serves as a practical example of how the company converts scientific innovation into recurring cash flows. These therapies contribute directly to the $10.1 billion revenue reported for the second quarter of 2026 and help support the ongoing dividend program with the $2.52 per-share payment going ex-dividend on August 21, 2026.
Closing market snapshot
As of August 20, 2026, 4:00 p.m. ET, Amgen stock was quoted at $440.88 on the Nasdaq, with a market capitalization of $239.17 billion based on that closing price. At this level and with an annualized dividend of $10.08 per share derived from the $2.52 quarterly payment, income and growth considerations continue to converge in the current valuation of Amgen’s shares.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 20, 2026, 4:00 p.m. ET): $440.88 USD
Market cap: $239.17 billion (as of August 20, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: S&P 500
